News for Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix (OCUL) has received continued support from HC Wainwright & Co. as analyst Yi Chen reiterates the

Ocular Therapeutix (OCUL) stock rises as its Phase 3 trial for lead asset Axpaxli in wet AMD nears enrollment target. Read more here.

**media[638993]**

**media[625358]**

On May 6, 2025, Ocular Therapeutix (OCUL) was the subject of an updated analyst rating from Needham. Notably, analyst Serge Belanger maintained a "Buy" rating f

Ocular Therapeutix Inc (OCUL) demonstrates a robust proprietary hydrogel platform technology, positioning it as a leader in ophthalmic therapies.Despite a stro

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on retinal diseases, announced its financial results for the first quarter ending Mar

As of March 31, 2025, Ocular Therapeutix (OCUL) reported $349.7 million in cash and cash equivalents. The company anticipates that these funds, coupled with exp

\nRevenue: $10.7 million, falling short of the estimated $16.83 million, marking a 27.6% decrease year-over-year.Earnings Per Share (EPS): Reported at $(0.38), m

\n Ocular Therapeutix (OCUL) reports Q1 2025 revenue of $10.7 million, a 27.6% decline year-over-year. Net loss for Q1 2025 was $64.1 million or $0.38 per

**media[608641]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On March 21, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a significant transaction by acquiring an additional 350,000 shares of Codexis Inc. This

On March 18, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a strategic transaction involving Harrow Inc., a U.S.-based eyecare pharmaceutical compa

On March 6, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a strategic stock transaction involving Codexis Inc. The firm added 100,000 shares of Cod

On March 13, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a strategic stock transaction involving Codexis Inc. The firm added 85,000 shares of Cod

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on innovative treatments for retinal diseases, announced on March 7, 2025, the granti